Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Profit After Tax (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Profit After Tax for 9 consecutive years, with -$60.8 million as the latest value for Q1 2026.

  • For Q1 2026, Profit After Tax changed 0.08% year-over-year to -$60.8 million; the TTM value through Mar 2026 reached -$219.0 million, down 7.8%, while the annual FY2025 figure was -$219.0 million, 29.56% down from the prior year.
  • Profit After Tax hit -$60.8 million in Q1 2026 for Bicycle Therapeutics, down from -$20.2 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$20.2 million in Q4 2025 and bottomed at -$79.0 million in Q2 2025.
  • Average Profit After Tax over 5 years is -$43.7 million, with a median of -$42.6 million recorded in 2023.
  • On a YoY basis, Profit After Tax climbed as much as 61.09% in 2025 and fell as far as 128.72% in 2025.
  • Bicycle Therapeutics' Profit After Tax stood at -$30.0 million in 2022, then crashed by 63.9% to -$49.1 million in 2023, then decreased by 5.42% to -$51.8 million in 2024, then soared by 61.09% to -$20.2 million in 2025, then tumbled by 201.68% to -$60.8 million in 2026.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$60.8 million, -$20.2 million, and -$59.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.